New strategies for the treatment of obesity and metabolic dysfunctions
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist Induced Nausea and Emesis in Preclinical Models — Hayes Lab
The role of GLP-1 and GIP in glucose homeostasis. Key defects in... | Download Scientific Diagram
Efficacy and safety of LY3298176, a GIP/GLP-1 receptor co-agonist, in subjects with type 2 diabetes: a phase 2b study - Media Centre | EASD
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial - The Lancet
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update - Nauck - 2021 - Diabetes, Obesity and Metabolism - Wiley Online Library
Blutzucker- und Gewichtsregulation bei Typ-2-Diabetes: Der duale GIP/GLP-1-Rezeptor-Agonist Tirzepatid ist Semaglutid überlegen
How May GIP Enhance the Therapeutic Efficacy of GLP-1?: Trends in Endocrinology & Metabolism
Tirzepatid in den USA zugelassen | PZ – Pharmazeutische Zeitung
Neue Diabetemedikamente Typ-2-Diabetes - diabetes-news : diabetes-news
Intracellular actions of GIP and GLP-1 on the-cell. Several cellular... | Download Scientific Diagram
GLP-1: Actions on Beta-cell Mass and Function
GLP-1/GIP Agonists in Obesity and Type 2 Diabetes | Pri-Med
Inkretinmimetika – Wikipedia
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial - The Lancet
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology | Full Text
Typ-2-Diabetes: Dualer GIP/GLP-1-Rezeptoragonist Tirzepatid bewirkt bessere glykämische Kontrolle
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment | Pharmacological Reviews
Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes - ScienceDirect
Biology | Free Full-Text | Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes – touchENDOCRINOLOGY
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells | Science Advances
Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/glucagon triple agonist in the neurodegenerative disease models - Media Centre | EASD
Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation - ScienceDirect
GIP and Glycemic Impact | Explore GIP
